Publications

Thank you for your interest in BHE’s publications. On this page, you will find a list of our peer-reviewed journal articles and abstracts presented at medical meetings, categorized by therapeutic area. Journal articles may be downloaded by clicking the BHE# at the end of the citation, but you will need to log in or register before downloading (see link at left). Downloads are subject to our terms and conditions.

Table of Contents:

Manuscripts

Alzheimer’s Disease
Cardiovascular Disease
Chronic Respiratory Disease
Diabetes
Hemorrhage
Infection
Migraine
Oncology
Schizophrenia
Sleep Disorders

Abstracts

Alzheimer’s Disease
Cardiovascular Disease
Chronic Respiratory Disease
Diabetes
Epilepsy
Erectile Dysfunction
Hemorrhage
Infection
Migraine
Multiple Sclerosis
Methods and Policy
Oncology
Pain Management

Manuscripts

Alzheimer’s Disease

  • Martin BC, Ricci JF, Kotzan JA, Lang K, Menzin J. The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord. 2000;14(3):151-159. BHE #0227
  • Menzin J, Lang K, Friedman M, Neumann P, Cummings J. The economic cost of Alzheimer’s disease and related dementias to the California Medicaid (”Medi-Cal”) Program in 1995. Am J Geriatr Psychiatry. 1999;7(4):300-308. BHE #3064

Cardiovascular Disease

  • Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Cur Med Res Opin. 2008; 24(2):461-468. BHE#11995
  • Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006; 60(3):258-264. BHE#10194
  • Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, Hurley JS, Pezzella S, Kaatz S. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study. Ann Pharmacother. 2005;39(3):446-51. BHE#8671
  • Menzin J, Foster T, Audette R. Socioeconomic implications of long-term warfarin use. Dis Manag Health Outcomes. 2004;12(6):385-92. BHE#8255
  • Menzin J, Lang K, Elliott WJ, Boulanger L, Arocho R, Tran MH, Friedman, M. Adherence to calcium channel blocker therapy in older adults: a comparison of amlodipine and felodipine. J Int Med Res. 2004 May-Jun;32(3):233-9. BHE#7291
  • Pegus C, Bazzarre TL, Brown JS, Menzin J. Effect of the Heart at Work program on awareness of risk factors, self-efficacy, and health behaviors. J Occup Environ Med. 2002; 44(3):228-36. BHE#4717

Chronic Respiratory Disease

  • Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the Economic Burden of COPD in the U.S.: A Review and Synthesis of the Literature. COPD. 2006; 3(4): 211-218. BHE#10581
  • Marton J, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J. Assessing the costs of chronic obstructive pulmonary disease: The state Medicaid perspective. Respir Med. 2006; 100(6):996-1005. BHE#9665
  • Miller JD, Foster T, Boulanger L, Chace M, Russell MW, Marton JP, Menzin J. Direct costs of COPD in the U.S.: An analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005;2(3):311-318. BHE#9413

Diabetes

  • Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: A managed-care perspective. Diabetes Care. 2001;24(1):51-5. BHE#2690

Hemorrhage

  • Boulanger L, Joshi AV, Tortella BJ, Menzin J, Caloyeras JP, Russel MW. Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma patients: Findings from the National Trauma Data Bank. Am Surg. 2007: 73:1269-1274. BHE#12000
  • Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J. Predictors of Hospital Length of Stay and Cost in Patients with Intracerebral Hemorrhage. Neurology. 2006; 67(7): 1279-81. BHE#10871
  • Russell MW, Boulanger L, Joshi AV, Neumann PJ, Menzin J. The Economic Burden of Intracerebral Hemorrhage: Evidence from U.S. Managed Care. Manag Care Interface. 2006; 19(6):24-29. BHE#10637
  • Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, Wygant G, Menzin J. Warfarin Exposure and the Risk of Thromobembolic and Major Bleeding Events Among Medicaid Patients with Atrial Fibrillation. Ann Pharmacother. 2006; 40(6):1024-1029. BHE#10576

Infection

  • Menzin J, Lang KM, Friedman M, Dixon D, Marton JP, Wilson J. Excess mortality, length of stay, and costs associated with serious fungal infections among elderly cancer patients: Findings from linked SEER-Medicare data. Value Health. 2005;8(2):140-8. BHE#8849

Migraine

  • Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J. Migraine Frequency and Health Utilities: Findings from a Multi-Site Survey. Value Health. BHE#11750
  • Brown JS, Rupnow MFT, Neumann P, Friedman M, Menzin J. Cost Effectiveness of Topiramate in the Prevention of Migraines in the United States: An Update. Manag Care Interface. 2006; 19(12): 31-38. BHE#11315
  • Brown JS, Papadopoulos G, Neumann P, Price M, Friedman M, Menzin J. Cost-Effectiveness of Migraine Prevention: The Case of Topiramate in the United Kingdom. Cephalalgia. 2006; 26(12): 1473-82. BHE#11047
  • Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J, Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache. 2005;45:1012-1022. BHE#9251

Oncology
Head and Neck

  • Menzin J, Lines LM, Manning LN. The Economics of Squamous Cell Carcinoma of the Head and Neck. Curr Opin Otolaryngol Head Neck Surg. 2007; 15: 58-73. BHE#11584
  • Lang K, Menzin J, Earle C, Jacobson J, Hsu MA. The economic cost of squamous cell cancer of the head and neck: Findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130:1269-75. BHE#7727

Leukemia

  • Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in treatment of acute myeloid leukemia in the elderly. Drugs Aging. 2005; 22(11):943-955. BHE#9604
  • Menzin J, Lang K, Earle C, Glendenning GA. Treatment patterns and outcomes among elderly patients with chronic myeloid leukemia: A population based analysis. Drugs Aging. 2004; 21(11):737-46. BHE#7587
  • Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002; 162(14):1597-603. BHE#4715
  • Lang K, Menzin J, Earle CC, Mallick R. Outcomes in patients treated with gemtuzumab ozogamicin for relapsed acute myelogenous leukemia. Am J Health Syst Pharm. 2002; 59(10):941-8. BHE#4716

Schizophrenia

  • Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003; 54:719–23. BHE#6443

Sleep Disorders

  • Menzin J, Lang K, Levy P, Levy E. A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. Pharmacoeconomics. 2001;19(1):69-78. BHE#3065

Abstracts

Alzheimer’s Disease

  • Boulanger L, Friedman M, Chang S, Dixon D, Menzin J. Economic impact of rivastigmine therapy among patients with Alzheimer’s disease: A Medicaid perspective. Int Psychogeriatr. 2003;15(Supplement 15):298-9.
  • Menzin J, Boulanger L, deFriesse R, Friedman M, Neumann P. A comparative cost analysis of Alzheimer’s disease versus vascular dementia. Value Health. 2003;6(3):196.
  • Boulanger L, Friedman M, Chang S, Neumann P, Arcona S, Menzin J. Rates of use of acetylcholinesterase inhibitors among patients newly diagnosed with Alzheimer’s disease. Poster presented at the American Association for Geriatric Psychiatry (AAGP) Annual Meeting in Honolulu, HI, March 2003.
  • Menzin J, Boulanger L, Neumann P, Friedman M, Chang S, Arcona S. The impact of acetylcholinesterase inhibitor treatment on nursing home admissions among patients with Alzheimer’s disease in the California Medicaid program. Poster presented at the American Association for Geriatric Psychiatry (AAGP) Annual Meeting in Honolulu, HI, March 2003.

Cardiovascular Disease

  • Menzin J, Zhang B, Friedman M, Charland SL, Burge RT. A model-based analysis of the effects of intensifying lipid-altering therapy on coronary heart disease event rates in a secondary prevention population with high non-HDL cholesterol. Poster presented at American Heart Association’s Scientific Sessions, November 4-7, 2007, Orlando, FL.
  • Zhang B, Friedman M, Charland SL, Burge RT, Simko RJ, Menzin J. A model-based analysis of the effects of intensifying lipid-altering therapy on direct medical costs of coronary heart disease events in a secondary prevention population in the United States. Value Health 2007; 10(6):PCV19 (Poster presented at ISPOR Europe 2007).
  • Menzin J, Wygant G, Hauch O, Friedman M, Jackel JL. One-year Costs of Ischemic Heart Disease Among Patients with Acute Coronary Syndromes: Findings from a Multi-Employer Claims Database. Presented at the Academy of Managed Care Pharmacy’s (AMCP) 2007 Educational Conference in Boston, Massachusetts, October 2007.
  • Menzin J, Boulanger L, Tang S, Thakker KM, Nissen SE. Economic Impact of Amlodipine in Normotensive Coronary Artery Disease Patients: Subgroup Analyses of Participants in the CAMELOT Trial. 1026-168. J Am Coll Cardiol. 2006; 49(9, Supplement A): 413A.
  • Menzin J, Boulanger L, Tang S, Thakker KM, Nissen SE. Effects of Amlodipine or Enalapril versus Placebo on Rates of Cardiovascular Hospitalization and Costs Among Coronary Artery Disease Patients With Normal Blood Pressure: Findings from the CAMELOT Economic Sub-study. P-109. J Clin Hypertens. 2006; 8(5, Suppl A):A52-53
  • Menzin J, Boulanger L, Tang S, Thakker KM, Nissen SE. Effects of Amlodipine or Enalapril versus Placebo on Rates of Cardiovascular Hospitalization and Costs Among Coronary Artery Disease Patients With Normal Blood Pressure: Findings from the CAMELOT Economic Sub-study. 848-8. J Am Coll Cardiol. 2006; 47(4, Suppl A):361A.
  • Boulanger L, Kim J, Friedman M, Hauch O, Menzin J. Quality of anticoagulation control among patients with atrial fibrillation in routine medical practice. Poster presented at Anticoagulation Forum 8th National Conference on Anticoagulation Therapy, in Orlando, Florida, May 2005.
  • Boulanger L, Kim J, Friedman M, Hauch O, Menzin J. Quality of anticoagulation control among patients with atrial fibrillation in routine medical practice. JACC. 2005; 45(Suppl. 3):334A.
  • Wilson J, Boulanger L, Friedman M, Dixon D, Menzin J. Racial disparities in prescription drug utilization: An analysis of beta-blocker and statin drug use following hospitalization for acute myocardial infraction. Circulation. 2004;109(20):31.
  • Boulanger L, Hauch O, Friedman M, Dixon D, Wygant G, Menzin J. Warfarin exposure and the risk of non-hemorrhagic stroke and bleeding events among Medicaid patients with atrial fibrillation: A retrospective analysis. Circulation. 2004;109(20):39.
  • Brown J, Menzin J, Manocchia M. Using health-risk appraisal data for assessing predictors of hypertension treatment. Value Health. 2004;7(3):318.
  • Menzin J, Brown J, Mannocchia M. How can health-risk appraisal data contribute to cardiovascular outcomes research? Workshop presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 9th Annual International Meeting in Arlington, VA, May 2004.
  • Boulanger L, Hauch O, Friedman M, Dixon D, Wygant G, Menzin J. Warfarin exposure and the risk of non-hemorrhagic stroke and bleeding events among Medicaid patients with atrial fibrillation: A retrospective analysis. Circulation. 2003;108(Supplement 17):IV-757.
  • Boulanger L, Hauch O, Wygant G, Dixon D, Friedman M, Menzin J. Rates of venous thromboembolism and associated inpatient healthcare resource use among patients undergoing major orthopedic surgery in an integrated delivery system. Value Health. 2003;6(3):316.
  • Menzin J, Brown JS, Friedman M, Saperia G, Boulanger L, Tran MH. Recent trends in the use of lipid-lowering medication: Findings from a managed care setting. Am Heart J. 2002;144(5):908.
  • Menzin J, Boulanger L, Marple CB, Friedman M, Wygant G, Hurley J, et al. Anticoagulation control and quality of monitoring warfarin therapy in clinic settings: A multisite managed care study. Am Heart J. 2002;144(5):917.
  • Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, et al. The cost of warfarin monitoring in anticoagulation clinics: A multi-site managed care study. Value Health. 2002;5(3):165.
  • Menzin J, Brown JS, Friedman M, Saperia G, Boulanger L, Tran M. Trends in the attainment of cholesterol treatment goals: Evidence from managed care. Value Health. 2002;5(3):162.
  • Menzin J, Boulanger L, Marple CB, Friedman M, Wygant G, Hurley JS, et al. Anticoagulation control and quality of monitoring warfarin therapy in clinic settings: a multi-site managed care study. Poster presented at the 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke in Washington, DC, September 30–October 1, 2001.

Chronic Respiratory Disease

  • Menzin J, Dastani H, Guadagno L, Dirani RG, Marton JP, Phillips AL, Shah H. The Health Status Burden of Chronic Obstructive Pulmonary Disease (COPD) in a U.S. Medicare Population: Findings from the Medicare Current Beneficiary Survey. RS3. Value Health. 2007; 10(3): A10-A11.
  • Menzin J, Boulanger L, Dastani H, Guadagno L, Marton J, Dirani R, Phillips A, Shah H. The Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in a U.S. Medicare Population. 431. Am J Respir Crit Care Med. 2007; 175(Abstracts): A779.
  • Boulanger L, Syat B, Rosiello R, Marton JP, Emani S, Migausky S, Menzin J. Gender-Based Differences in Hospitalization Rates for Chronic Obstructive Pulmonary Disease: Findings from a Disease Management Program. Chest Meeting Abstracts. 2006; 130(4): 84S.
  • Menzin J, Brown JS, Guadagno L, Friedman M, Kitch B, Marton JP, Best C, Boulanger L, Xuan J. Care-Seeking Behavior Among Subjects with Early Chronic Obstructive Lung Disease Identified Through a Community Spirometry Screening Program: Findings from the Respiratory Health Promotion Study (RHPS). 223. Chest Meeting Abstracts. 2006; 130(4): 170S.
  • Miller JD, Marton JP, Kitch BT, Neumann PJ, Mansfield CJ, Menzin J. Lifetime Costs and Impact on Life Expectancy of Chronic Obstructive Pulmonary Disease (COPD) in the U.S.: Projections From a Decision-Analytic Model. PRS4. Value Health. 2006; 9(3):A93.
  • Menzin J, Brown JS, Guadagno L, Friedman M, Kitch B, Marton JP, Brodney Folse S, Xuan J. Predictors of Obstructive Lung Disease in the Community: Interim Findings from the Respiratory Health Promotion Study. Proc Am Thorac Soc. 2006; 3(Abstracts Issue):A616.
  • Menzin J, Brown JS, Guadagno L, Friedman M, Kitch B, Marton JP, Brodney Folse S, Neumann P, Xuan J. Health Status of Persons with Respiratory Disease Identified via a Spirometry Screening Program: Interim Findings from the Respiratory Health Promotion Study. Proc Am Thorac Soc. 2006; 3(Abstracts Issue):A602.
  • Menzin J, Brown JS, Guadagno L, Simmons M, Kitch B, Marton JP, Friedman M, Xuan J. Implementation of a community-based spirometry screening program: Lessons from the Respiratory Health Promotion Study (RHPS). Poster presented at American Public Health Association’s (APHA) 133rd Annual Meeting & Exposition in Philadelphia, PA, December 2005. 112028.
  • Marton JP, Menzin J, Brown JS, Kitch B, Friedman M, Guadagno L, Xuan J. Comparison of Respiratory Disease Burden for Chronic Obstructive Lung Disease versus an “At-Risk” Group: Early findings from the Respiratory Health Promotion Study (RHPS). Chest Meeting Abstracts. 2005; 128(4):159S.
  • Menzin J, Miller JD, Kitch BT, Friedman M, Marton JP. Impact of smoking cessation on future burden of chronic obstructive pulmonary disease (COPD) in the U.S.: Projections from a COPD population-based model. Proc Amer Thorac Soc. 2005; 2(Abstracts):A571.
  • Miller JD, Boulanger L, Russell MW, Marton J, Menzin J. Estimating the number of cases of diagnosed chronic obstructive pulmonary disease (COPD): Use of medical claims data versus alternative methodologies. PRS4. Value Health. 2005; 8(3):326.
  • Menzin J, Brown JS, Manocchia M, Kitch B, Marton JP, Friedman M, Xuan J. Prevalence and awareness of respiratory disease in community settings: Early findings from the Respiratory Health Promotion Study (RHPS). J119. Proc Amer Thorac Soc. 2005; 2(Abstracts):A411.
  • Boulanger L, Menzin J, Marton J, Friedman M, Dixon D, Xuan J. National estimates of ambulatory visits for major respiratory conditions. Chest. 2004; 126(4):727S.
  • Marton J, Enuha S, Boulanger L, Friedman M, Xuan J, Menzin J. National estimates of hospitalizations for major respiratory conditions. Chest. 2004; 126(4):728S.
  • Enuha S, Marton J, Boulanger L, Friedman M, Xuan J, Menzin J. National estimates of work loss for major respiratory conditions. Chest. 2004; 126(4):728S.
  • Boulanger L, Marton JP, Friedman M, Dixon D, Menzin J. The excess cost of chronic obstructive pulmonary disease from a managed-care perspective. Value Health. 2004;7(3):222.
  • Brown J, Marton JP, Friedman M, Chace M, Menzin J. Episodes of respiratory care for managed care patients with COPD: Assessing the economic burden. Value Health. 2004;7(3):257.
  • Miller JD, Foster T, Boulanger L, Chace M, Marton JP, Wilson J, Menzin J. Costs of chronic obstructive pulmonary disease (COPD) in the U.S.: An analysis of Medical Expenditure Panel Survey (MEPS) data. Am J Respir Crit Care Med. 2004;169(Supplement 7):A609.
  • Menzin J, Boulanger L, Friedman M, Dixon D, Marton J, Wilson J. Respiratory-related healthcare costs for patients with COPD: A state Medicaid perspective. Am J of Resp and Crit Care Med. 2003;167(7):A240.
  • Marton J, Boulanger L, Menzin J, Friedman M, Dixon D, Wilson J. The cost of chronic obstructive pulmonary disease from a state Medicaid program perspective. Value Health. 2003;6(3):183.

Diabetes

  • Menzin J, Brown JS, Friedman M, Saperia G, Graham LA. Cholesterol goal attainment in patients with diabetes: Evidence from managed care. Value Health. 2003;6(3):177.

Epilepsy

  • Boulanger L, Friedman M, Chang S, Yong M, Neumann P, Menzin J. The effects of oxcarbazepine versus carbamazepine therapy on healthcare utilisation and costs among epilepsy patients in a managed care setting. Epilepsia. 2002;43(Suppl. 8):122.

Erectile Dysfunction

  • Boulanger L, Harnett J, Menzin J. The Excess Prevalence of Comorbidities Associated with Erectile Dysfunction in a Large State Medicaid Program. PIH1. Value Health. 2006; 9(3):A50.

Hemorrhage

  • Russell MW, Boulanger L, Joshi AV, Neumann PJ, Menzin J. Racial/Ethnic Disparities in Length of Stay and Cost of Inpatient Care for Intracerebral Hemorrhage: Evidence from the Health Care Cost and Utilization Project Database. HE4. Value Health. 2006; 9(3):A13-A14.
  • Russell MW, Joshi AV, Boulanger L, Neumann PJ, Menzin J. Intracerebral Hemorrhage versus Ischemic Stroke: Differences in Hospitalization Outcomes. 1190. J Neurol Sci. 2005; 238(Suppl 1): S404.
  • Russell MW, Boulanger L, Joshi AV, Neumann PJ, Menzin J. The Economic Burden of Intracerebral Hemorrhage: A US Managed Care Cost-of-Illness Study. 1189. J Neurol Sci. 2005; 238(Suppl 1): S403-S404.
  • Russell MW, Joshi AV, Boulanger L, Neumann PJ, Menzin J. Surgical vs. Nonsurgical Intervention in Intracerebral Hemorrhage: Evidence from the AHRQ Healthcare Cost and Utilization Project Database. Poster was presented at the Congress of Neurological Surgeons (CNS) 55th Annual Meeting, in Boston, MA, October 2005.
  • Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J. Impact of patient, hospital, and payer characteristics on hospital outcomes in intracerebral hemorrhage. 20. Ann Neurol. 2005; 58(S9):S8.
  • Russell MW, Joshi AV, Neumann PJ, Boulanger L, Menzin J. High Proportions of Brain Hemorrhages are Admitted via the Emergency Department and are Associated with High Inpatient Mortality and Cost. 204. Ann Emer Med. 2005; 46(Supplement 2, #3):S57.

Infection

  • Menzin J, Wygant G, Hauch O, Friedman M, Jackel JL. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Poster presented at the Academy of Managed Care Pharmacy’s (AMCP) 2007 Educational Conference in Boston, Massachusetts, October 2007.
  • Marton JP, Jackel JL, Carson RT, Rothermel CD, Menzin J. Predictors of costs for skin and skin structure infections due to Staphylococcus aureus using a managed-care perspective. Value Health 2007; 10(6):PIN34 (Poster presented at ISPOR Europe).
  • Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Papadopoulos G. Clinical and economic burden of invasive fungal infections among hospitalized patients: Findings from a US national database. O-1869. Poster presented at the 47th ICAAC Meeting of the American Society for Microbiology in Chicago, Illinois, September 2007.
  • Marton JP, Menzin J, Sussman M, Friedman M, Philburn RT, Rothermel CD. The Clinical and Economic Burden of Complicated Skin and Skin Structure Infections due to Staphylococcus Aureus: Findings from a National Database. PIN21. Value Health. 2007; 10(3): A165-A166.
  • Menzin J, Marton JP, Sussman M, Friedman M, Philburn RT, Mendelson MH. The Economic Burden of Ventilator-Associated Pneumonia Due to Staphylococcus Aureus: Findings from a National Database. IN3. Value Health. 2007; 10(3): A18-A19.
  • Boulanger L, Harnett J, Dixon D, Menzin J, Wilson J. Outcomes following the use of azithromycin or clarithromycin for respiratory tract infections in a Medicaid population. Value Health. 2004;7(3):351.
  • Menzin J, Lang K, Friedman M, Dixon D, Marton J, Wilson J. Excess mortality and costs associated with serious fungal infections among elderly cancer patients: Findings from linked SEER-Medicare data. Value Health. 2002;5(3):200.
  • Edelman-Lewis B, Menzin J, Boulanger L, Leung M, Friedman M, Hurley JS, et al. Patterns of antibiotic use and costs associated with episodes of treatment for common outpatient respiratory-tract infections: An analysis of managed-care data. Value Health. 2001;4(2):136-7.

Migraine

  • Brown JS, Rupnow MF, Neumann P, Friedman M, Menzin J. Cost-Effectiveness of Topiramate for Migraine Prevention: A Managed Care Perspective. PNL9. Value Health. 2006; 9(3):A82.
  • Brown JS, Rupnow M, Neumann P, Friedman M, Papadopoulos G, Menzin J. Cost-Effectiveness of Topiramate for Migraine Prevention: A Managed Care Perspective. P04?96. Poster presented at the American Academy of Neurology’s (AAN) 58th Annual Meeting in San Diego, CA, April 2006.
  • Brown J, Neumann P, Papadopoulos G, Ruoff G, Maizels M, Diamond M, Menzin J. Impact of migraine frequency on health utilities. PNL14. Value Health. 2005; 8(3):318.
  • Brown JS, Ruoff G, Neumann P, Papadopoulos G, Maizels M, Diamond M, Menzin J. Patient health perceptions and the burden of migraine: A multi-site study. P05.068. Neurology. 2005; 64(6 Suppl.1):A309.
  • Brown J, Papadopoulos G, Neumann P, Friedman M, Menzin J. Cost-effectiveness of migraine prevention: Results from a model of topiramate treatment. Value Health. 2004;7(3):237.

Multiple Sclerosis

  • Boulanger L, Friedman M, Dixon D, Menzin J. Health care costs for Florida Medicaid recipients with multiple sclerosis. Value Health. 2004;7(3):291.

Methods and Policy

  • Menzin J, Neumann P, Cohen JT. Risk-benefit assessment and cost-effectiveness analysis: Differences, similarities, and synergies. W26. Workshop presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual International Meeting in Washington, D.C., May 2005.
  • Boulanger L, Brown J, Menzin J. Medicaid drug spending after the Medicare Modernization Act: What will be left? HP1. Value Health. 2005; 8(3):237.
  • Menzin J, Hartnett J. Budgetary impact analyses for state Medicaid programs: One model or fifty? Workshop presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 8th Annual International Meeting in Arlington, VA, May 2003.
  • Brown JS, Menzin J, Friedman M. Sources of variation in drug costs among state Medicaid programs. Value Health. 2003;6(3):204.
  • Menzin J, Lang K. Using linkable clinical and administrative claims data to improve outcomes research: Selected case studies from oncology and diabetes mellitus. Value Health. 2001;4(2):189.

Oncology
Head and Neck

  • Jacobson J, Lang K, Menzin J. The health economic cost of squamous cell cancer of the head and neck in the elderly. Poster presented at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, FL, May 2002.
  • Hsu MA, Menzin J, Lang K, Jacobson J. Treatment patterns of outcomes among patients with squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Poster presented at the American Society of Clinical Oncology (ASCO) 38th Annual Meeting in Orlando, FL, May 2002.

Leukemia

  • Menzin J, Boulanger L, Karsten V, Cahill AL, Earle CE. Effects of Initial Treatment on Survival Among Elderly AML Patients: Findings from the SEER-Medicare Database. 1973. Blood. 2006; 108(11).
  • Menzin J, Lang K, Earle C, Foster T, Dixon D, Van Gool R. Treatment patterns and costs associated with acute myeloid leukemia in the elderly: A population based analysis. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; 22, No 14S(July 15 Supplement):6613.
  • Menzin J, Lang K, Earle C, Glenndenning A. Treatment patterns and outcomes among elderly patients with chronic myeloid leukemia. Blood. 2002;100:875a

Prostate

  • Lee DW, Dann RA, Lintner MJ, Zhang B, Friedman M, Park G, Menzin J. International incidence of men with uncertain indication for radical prostatectomy: an evidence-based analysis. Value Health. 2007; 10(6): PCN56 (Poster presented at ISPOR Europe 2007).

Pain Management

  • Miller JD, Russell MW, Neumann PJ, Menzin J, Rublee DA, Boye ME. A UK Pharmacoeconomic Model of Parenteral Parecoxib vs. Opioid Analgesia Following Major Surgery. PPN6. Value Health. 2005; 8(6): A141.
  • Russell MW, Miller JD, Neumann PJ, Menzin J, Boye ME, Rublee DA. A U.S. Pharmacoeconomic Model of Parenteral Parecoxib vs. Opioid and Ketorolac Analgesia Following Major Surgery. 259. Pharmacotherapy. 2005; 25(10):1490.